摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-phenyl-2-[(phenylmethyl)thio]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one hydrochloride | 1016975-40-8

中文名称
——
中文别名
——
英文名称
3-phenyl-2-[(phenylmethyl)thio]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one hydrochloride
英文别名
2-(benzylthio)-3-phenyl-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one hydrochloride;2-benzylsulfanyl-3-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one;hydrochloride
3-phenyl-2-[(phenylmethyl)thio]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one hydrochloride化学式
CAS
1016975-40-8
化学式
C20H19N3OS*ClH
mdl
——
分子量
385.917
InChiKey
NZHNBEHLTYTKOI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.59
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    70
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • PYRIMIDIN-4-(3H)-ONE DERIVATIVES
    申请人:Arakawa Keisuke
    公开号:US20110275647A1
    公开(公告)日:2011-11-10
    The present invention relates to a compound represented by a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 represents lower alkyl or the like; R 2 represents phenyl or the like; R represents a halogen atom or the like; X represents an oxygen atom or the like; Y 1 , Y 2 , Y 3 and Y 4 represent CH or the like; l represents an integer of from 0 to 3; m and n each represent an integer of 1 or 2; p represents an integer of from 0 to 2; and q represents an integer of from 1 to 3.
    本发明涉及一种由式(I)表示的化合物或其药学上可接受的盐,其中R1代表较低的烷基或类似物;R2代表苯基或类似物;R代表卤素原子或类似物;X代表氧原子或类似物;Y1、Y2、Y3和Y4代表CH或类似物;l表示0到3的整数;m和n各代表1或2的整数;p表示0到2的整数;q表示1到3的整数。
  • COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND
    申请人:Dainippon Sumitomo Pharma Co., Ltd.
    公开号:EP2078719A1
    公开(公告)日:2009-07-15
    The present invention relates to a bicyclic pyrimidine compound of the following formula (I) or a salt thereof. wherein R1 is lower alkyl, cyclic lower alkyl. etc.; R2 is H, lower alkyl, lower alkenyl, etc.; R3 is H, lower alkyl, lower alkenyl, etc.; X is O, S or -N(R4)-; R4 is H or lower alkyl; or R2 and R4 may combine each other to form cyclic amino; Y is amido, keto, sulfonyl, etc.; R5 is H or lower alkyl; Z is O or S; m and n are 1 or 2. Said compound (I) or a salt thereof have MGAT inhibitory activity, and are useful as an agent for treatment or prophylaxis of adiposity, metabolic syndromes, hyperlipidemia, hyper neutral lipemia, hyper VLDL-mia, hyper fatty acidemia, diabetes mellitus, arteriosclerosis.
    本发明涉及下式(I)的双环嘧啶化合物或其盐。 其中 R1 是低级烷基、环状低级烷基等;R2 是 H、低级烷基、低级烯基等;R3 是 H、低级烷基、低级烯基等;X 是 O、S 或 -N(R4)-;R4 是 H 或低级烷基;或 R2 和 R4 可相互结合形成环状氨基;Y 是氨基、酮基、磺酰基等;R5 是 H 或低级烷基;Z 是 O 或 S;m 和 n 是 1 或 2。所述化合物(I)或其盐具有 MGAT 抑制活性,可用于治疗或预防肥胖症、代谢综合征、高脂血症、高中性脂血症、高 VLDL-血症、高脂肪酸血症、糖尿病、动脉硬化。
  • Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
    申请人:Nakamura Keiji
    公开号:US20100093771A1
    公开(公告)日:2010-04-15
    The present invention relates to a bicyclic pyrimidine compound of the following formula (I) or a salt thereof. wherein R 1 is lower alkyl, cyclic lower alkyl. etc.; R 2 is H, lower alkyl, lower alkenyl, etc.; R 3 is H, lower alkyl, lower alkenyl, etc.; X is O, S or —N(R 4 )—; R 4 is H or lower, alkyl; or R 2 and R 4 may combine each other to form cyclic amino; Y is amido, keto, sulfonyl, etc.; R 5 is H or lower alkyl; Z is O or S; m and n are 1 or 2. Said compound (I) or a salt thereof have MGAT inhibitory activity, and are useful as an agent for treatment or prophylaxis of adiposity, metabolic syndromes, hyperlipidemia, hyper neutral lipemia, hyper VLDL-mia, hyper fatty acidemia, diabetes mellitus, arteriosclerosis.
  • US8232282B2
    申请人:——
    公开号:US8232282B2
    公开(公告)日:2012-07-31
  • [EN] PYRIMIDIN-4(3H)-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4(3H)-ONE
    申请人:BANYU PHARMA CO LTD
    公开号:WO2010095767A1
    公开(公告)日:2010-08-26
    The present invention relates to a compound represented by a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents lower alkyl or the like; R2 represents phenyl or the like; R represents a halogen atom or the like; X represents an oxygen atom or the like; Y1, Y2, Y3 and Y4 represent CH or the like; l represents an integer of from 0 to 3; m and n each represent an integer of 1 or 2; p represents an integer of from 0 to 2; and q represents an integer of from 1 to 3.
    本发明涉及一种由式(I)表示的化合物或其药学上可接受的盐,其中R1代表低碳烷基或类似物; R2代表苯基或类似物; R代表卤素原子或类似物; X代表氧原子或类似物; Y1、Y2、Y3和Y4代表CH或类似物; l表示0到3的整数; m和n各表示1或2的整数; p表示0到2的整数; q表示1到3的整数。
查看更多

同类化合物

阿昔替酯 螺喹唑啉 苯并[g][1,2,3]三唑并[4',5':5,6]吡啶并[2,1-b]喹唑啉-13(2H)-酮 脱氢利培酮 盐酸曲林菌素 甲硫利马唑 甲基8-乙基-2-甲氧基-5-氧代-5,8-二氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基8-乙基-2-(甲硫基)-5-氧代-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基2-乙氧基-8-乙基-5-氧代-吡啶并[6,5-d]嘧啶-6-羧酸酯 溴他替尼 泮托拉唑杂质DF 氨甲酸,[(2R,3E)-2-羟基-3-戊烯基]-,1,1-二甲基乙基酯(9CI) 柱孢藻毒素 曲美替尼 曲美替尼 曲喹辛 帕潘立酮棕榈酸酯 帕潘立酮杂质7 帕潘立酮杂质 帕潘立酮杂质 帕潘立酮 帕泊昔布杂质117 帕利哌酮十四酸酯 帕利哌酮N-氧化物 布喹特林 巴马斯汀 奥卡哌酮 多夸司特 吡曲克辛 吡嘧司特钾 吡嘧司特 吡啶并[4,3-d]嘧啶-4(1H)-酮,4,5,6,7-四氢-6-甲基-2-苯基- 吡啶并[4,3-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,4-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,2-d]嘧啶-4(3H)-酮,3-甲基-2-(甲基氨基)- 吡啶并[3,2-d]嘧啶-4(3H)-酮 吡啶并[3,2-d]嘧啶-4(1H)-酮,2,3-二氢-3-(2-羟基苯基)-2-硫代- 吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮 吡啶并[2,3-d]嘧啶-7(8h)-酮,2,6-二溴-8-环戊基-5-甲基- 吡啶并[2,3-d]嘧啶-7(8H)-酮 吡啶并[2,3-d]嘧啶-7(1H)-酮,4-氨基-5,6-二氢-5-甲基- 吡啶并[2,3-d]嘧啶-6-羧酸,1-(2,4-二甲基苯基)-1,4-二氢-2,7-二甲基-4-羰基-,酰肼 吡啶并[2,3-d]嘧啶-4(3H)-酮,5,7-二甲基-2-(甲硫基)-3-苯基- 吡啶并[2,3-d]嘧啶-4(3H)-酮 吡啶并[2,3-d]嘧啶-4(1H)-酮,2,3-二氢-1-(4-甲基苯基)-2-硫代- 吡啶并[2,3-d]嘧啶-2-胺 吡啶并[2,3-d]嘧啶 吡啶并[2,3-D]嘧啶-4-胺 吡啶并[2,3-D]嘧啶-2,4,7(1H,3H,8H)-三酮 吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮